Viridian Therapeutics, Inc.
VRDN· Nasdaq
VRDNViridian Therapeutics, Inc.
Filed Mar 14, 2019 · 10-K · 73 days after period end · 0001590750-19-000013
| Metric | Q4 2018 | Q4 2017 | Q4 2016 | Q4 2015dderived from reported figures |
|---|---|---|---|---|
| Revenue | $476.00K | $1.19M | $509.00K | $1.60M |
| Net Income | -$10.32M | -$6.39M | -$5.97M | -$2.98M |
| EPS Diluted | -$0.33 | -$0.29 | -$9.20 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
ended Dec 31, 2018 · filed Mar 14, 2019 · 73 d after period end
